Detail
| LncRNA Name | PRCAT17.3 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR etc. |
| Sample | prostate cancer tissues, cell line (PC3) |
| Expression Pattern | up-regulated |
| Function Description | Our data revealed that the expression levels of PRCAT17.3 (P<0.0001) and PRCAT38 (P<0.0002) were significantly upregulated in human prostate cancer tissues, compared to BPH ones. Moreover, the altered expression was much higher for PRCAT17.3 (ï½?2000 folds) than PRCAT38 (ï½?50 folds). Moreover, real-time RT-PCR analyses on urine samples of prostate cancer patients revealed that prcat17.3 level is significantly elevated, (P<0.0197; AUC-ROC value of 0.72), compared to that of BPH patients. |
| Pubmed ID | 29671889 |
| Year | 2018 |
| Title | Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. |
| External Links |
| Links for PRCAT17.3 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.